Alzheimer’s disease (AD) is the most prevalent dementia disorder globally, and there are still no effective interventions for slowing or stopping the underlying pathogenic mechanisms. There is strong evidence implicating neural oxidative stress (OS) and ensuing neuroinflammation in the progressive neurodegeneration observed in the AD brain both during and prior to symptom emergence. Thus, OS-related biomarkers may be valuable for prognosis and provide clues to therapeutic targets during the early presymptomatic phase. In the current study, we gathered brain RNA-seq data of AD patients and matched controls from the Gene Expression Omnibus (GEO) to identify differentially expressed OS-related genes (OSRGs). These OSRGs were analyzed for cellular functions using the Gene Ontology (GO) database and used to construct a weighted gene co-expression network (WGCN) and protein-protein interaction (PPI) network. Receiver operating characteristic (ROC) curves were then constructed to identify network hub genes. A diagnostic model was established based on these hub genes using Least Absolute Shrinkage and Selection Operator (LASSO) and ROC analyses. Immune-related functions were examined by assessing correlations between hub gene expression and immune cell brain infiltration scores. Further, target drugs were predicted using the Drug-Gene Interaction database, while regulatory miRNAs and transcription factors were predicted using miRNet. In total, 156 candidate genes were identified among 11046 differentially expressed genes, 7098 genes in WGCN modules, and 446 OSRGs, and 5 hub genes (MAPK9, FOXO1, BCL2, ETS1, and SP1) were identified by ROC curve analyses. These hub genes were enriched in GO annotations “Alzheimer’s disease pathway,” “Parkinson’s Disease,” “Ribosome,” and “Chronic myeloid leukemia.” In addition, 78 drugs were predicted to target FOXO1, SP1, MAPK9, and BCL2, including fluorouracil, cyclophosphamide, and epirubicin. A hub gene-miRNA regulatory network with 43 miRNAs and hub gene-transcription factor (TF) network with 36 TFs were also generated. These hub genes may serve as biomarkers for AD diagnosis and provide clues to novel potential treatment targets.
We investigate the persistent edge currents for the parafermionic fractional quantum Hall ͑FQH͒ states on a cylinder. The currents are periodic with the unit flux 0 ϭhc/e at all temperatures. In the low temperature limit, a sequence of the parafermionic FQH states show additional oscillations. In these cases, the periods of the oscillations become 0 /k with kϭ1,2,3, . . . , indicating the collective motion of k particles.
The identification of cancer subtypes can help researchers understand hidden genomic mechanisms, enhance diagnostic accuracy and improve clinical treatments. With the development of high-throughput techniques, researchers can access large amounts of data from multiple sources. Because of the high dimensionality and complexity of multiomics and clinical data, research into the integration of multiomics data is needed, and developing effective tools for such purposes remains a challenge for researchers. In this work, we proposed an entirely unsupervised clustering method without harnessing any prior knowledge (MODEC). We used manifold optimization and deep-learning techniques to integrate multiomics data for the identification of cancer subtypes and the analysis of significant clinical variables. Since there is nonlinearity in the gene-level datasets, we used manifold optimization methodology to extract essential information from the original omics data to obtain a low-dimensional latent subspace. Then, MODEC uses a deep learning-based clustering module to iteratively define cluster centroids and assign cluster labels to each sample by minimizing the Kullback–Leibler divergence loss. MODEC was applied to six public cancer datasets from The Cancer Genome Atlas database and outperformed eight competing methods in terms of the accuracy and reliability of the subtyping results. MODEC was extremely competitive in the identification of survival patterns and significant clinical features, which could help doctors monitor disease progression and provide more suitable treatment strategies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.